menu
    • menu

    Company profile for Novartis Pharmaceuticals Corporation

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals ...
    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals Corporation, we believe that all Americans deserve access to quality health care, including prescription medicines, health education about their disease or condition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novartis Pharmaceuticals CorporationSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    🎙️Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 214

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3947

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    PTC and Novartis’ Huntington's data fail to convince investors
    PTC and Novartis’ Huntington's data fail to convince investors

    07 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ptc-crashes-win-novartis-partnered-huntingtons-drug-fails-convince-investors

    FIERCE BIOTECH
    07 May 2025
    Share Share
    Incyte, Novartis reach settlement in Jakafi royalty dispute
    Incyte, Novartis reach settlement in Jakafi royalty dispute

    06 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/incyte-and-novartis-agree-settle-long-running-jakafi-royalty-dispute-just-trial

    FIERCE PHARMA
    06 May 2025
    Share Share
    BioNTech says Novartis executive Zapata to become CFO
    BioNTech says Novartis executive Zapata to become CFO

    05 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-novartis-executive-zapata-gomez-become-cfo-2025-05-05/

    REUTERS
    05 May 2025
    Share Share
    Novartis to buy Regulus in up to $1.7 Billion deal
    Novartis to buy Regulus in up to $1.7 Billion deal

    01 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-regulus-therapeutics-up-17-billion-2025-04-30/

    REUTERS
    01 May 2025
    Share Share
    Novartis builds momentum with new drug launches
    Novartis builds momentum with new drug launches

    29 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/novartis-builds-momentum-new-drug-launches-ceo-comfortable-navigating-us-tariffs-impact

    FIERCE PHARMA
    29 Apr 2025
    Share Share
    Novartis axes osteoarthritis asset and radioligand therapy
    Novartis axes osteoarthritis asset and radioligand therapy

    29 Apr 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-axes-osteoarthritis-asset-and-radioligand-therapy-after-seeing-clinical-data

    FIERCE BIOTECH
    29 Apr 2025
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Pentetreotide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Pentetreotide

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 9906

    Submission : 1992-10-09

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 227MF10097

    Registrant's Address : Lichtstrasse 35, CH-4056 Basel, Switzerland

    Initial Date of Registration : 2015-04-09

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Valsartan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Valsartan

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23902

    Submission : 2010-07-02

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2016-290 - Rev 03

    Issue Date : 2024-10-16

    Type : Chemical

    Substance Number : 2423

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Novartis Korea Ltd.

    Registration Date : 2011-12-09

    Registration Number : 20111209-135-H-172-28

    Manufacturer Name : Novartis Grimsby Ltd.

    Manufacturer Address : Moody Lane, Pyewipe, Grimsby_N.E. Lincolnshire/DN31 2SR/England

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Amlodipine Besylate

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Amlodipine Besylate

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2008-122 - Rev 02

    Issue Date : 2023-12-14

    Type : Chemical

    Substance Number : 1491

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 0078-1476

    Start Marketing Date : 2007-06-20

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Baclofen

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Baclofen

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 9643

    Submission : 1992-04-15

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Fluvastatin

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Fluvastatin

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23901

    Submission : 2010-06-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Glycolide - lactide copolymer

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Glycolide - lactide copolymer

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 6895

    Submission : 1987-03-26

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Letrozole

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Letrozole

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2019-149 - Rev 00

    Issue Date : 2020-09-03

    Type : Chemical

    Substance Number : 2334

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Novartis Korea Ltd.

    Registration Date : 2021-07-27

    Registration Number : 20210727-209-J-1080

    Manufacturer Name : Novartis Pharma Schweizerhalle AG@Novartis Pharma Stein AG

    Manufacturer Address : Rothausstrasse, 4133, Pratteln, Switzerland@Schaffhauserstrasse, 4332 Stein, Switzerland

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Lutetium Chloride Lu-177

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Lutetium Chloride Lu-177

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31705

    Submission : 2017-05-02

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    NAFTIFINE HCL

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    NAFTIFINE HCL

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 16772

    Submission : 2003-08-19

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Terbinafine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Arvo
    Not Confirmed
    arrow

    Terbinafine

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 27059

    Submission : 2013-06-07

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : G-Therapeutics Korea Co., Ltd.

    Registration Date : 2011-02-15

    Registration Number : 20110215-49-A-244-16

    Manufacturer Name : Novartis Ringaskiddy Limited

    Manufacturer Address : Ringaskiddy, Co. Cork

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    02

    Chlorthalidone Usp

    Switzerland
    Arvo
    Not Confirmed
    arrow

    03

    Eudragitr Rl/rs

    Switzerland
    Arvo
    Not Confirmed
    arrow

    04

    Fluvastatin Drug Substance

    Switzerland
    Arvo
    Not Confirmed
    arrow

    05

    06

    Lioresal Intrathecal Ampuls/baclofen

    Switzerland
    Arvo
    Not Confirmed
    arrow

    07

    Lutetium [177 Lu] Trichloride

    France
    Arvo
    Not Confirmed
    arrow

    08

    Lysine Hydrochloride (hci)-arginine ...

    France
    Arvo
    Not Confirmed
    arrow

    09

    Naftifine Hydrochloride

    Switzerland
    Arvo
    Not Confirmed
    arrow

    10

    Naphazoline Hydrochloride

    Switzerland
    Arvo
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Amlodipine besilate, Process II

    CEP/COS

    Arvo
    Not Confirmed
    arrow

    02

    Bovine Derived 0.6% Collagen Solution

    CEP/COS

    Arvo
    Not Confirmed
    arrow

    03

    Letrozole

    CEP/COS

    Arvo
    Not Confirmed
    arrow

    04

    Valsartan

    CEP/COS

    Arvo
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Acquires Regulus and Farabursen for ADPKD Treatment

    Details:

    Through the acquisition, Novartis will levarage Regulus pipeline, which includes RGLS8429 (farabursen), a potential next-gen oligonucleotide targeting miR-17 for the treatment of ADPKD.


    Lead Product(s): Farabursen

    Therapeutic Area: Genetic Disease Brand Name: RGLS8429

    Study Phase: Phase IProduct Type: Oligonucleotide

    Recipient: Regulus Therapeutics

    Deal Size: $1,700.0 million Upfront Cash: $800.0 million

    Deal Type: Acquisition April 30, 2025

    blank

    01

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Farabursen

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase I

    Recipient : Regulus Therapeutics

    Deal Size : $1,700.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis Acquires Regulus and Farabursen for ADPKD Treatment

    Details : Through the acquisition, Novartis will levarage Regulus pipeline, which includes RGLS8429 (farabursen), a potential next-gen oligonucleotide targeting miR-17 for the treatment of ADPKD.

    Product Name : RGLS8429

    Product Type : Oligonucleotide

    Upfront Cash : $800.0 million

    April 30, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CareMed Chosen As Specialty Pharmacy Partner For VANRAFIA

    Details:

    The partnership aims to distribute Novartis' Vanrafia (atrasentan HCl) through CareMed. It is indicated for the treatment of proteinuria in adults with primary immunoglobulin A nephropathy.


    Lead Product(s): Atrasentan

    Therapeutic Area: Nephrology Brand Name: Vanrafia

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: CareMed

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership April 07, 2025

    blank

    02

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : CareMed

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    CareMed Chosen As Specialty Pharmacy Partner For VANRAFIA

    Details : The partnership aims to distribute Novartis' Vanrafia (atrasentan HCl) through CareMed. It is indicated for the treatment of proteinuria in adults with primary immunoglobulin A nephropathy.

    Product Name : Vanrafia

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    April 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis has Completed the Acquisition of Anthos

    Details:

    Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.


    Lead Product(s): Abelacimab

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868

    Study Phase: Phase IIIProduct Type: Antibody

    Recipient: Anthos Therapeutics

    Deal Size: $3,075.0 million Upfront Cash: $925.0 million

    Deal Type: Acquisition April 03, 2025

    blank

    03

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Abelacimab

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Recipient : Anthos Therapeutics

    Deal Size : $3,075.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis has Completed the Acquisition of Anthos

    Details : Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.

    Product Name : MAA868

    Product Type : Antibody

    Upfront Cash : $925.0 million

    April 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Gets FDA Approval for Vanrafia® to Reduce Proteinuria in IgAN

    Details:

    Vanrafia (atrasentan HCl) is an investigational oral endothelin A receptor antagonist (ERA), which is approved for IgAN and early-stage development for other rare kidney diseases.


    Lead Product(s): Atrasentan

    Therapeutic Area: Nephrology Brand Name: Vanrafia

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 02, 2025

    blank

    04

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis Gets FDA Approval for Vanrafia® to Reduce Proteinuria in IgAN

    Details : Vanrafia (atrasentan HCl) is an investigational oral endothelin A receptor antagonist (ERA), which is approved for IgAN and early-stage development for other rare kidney diseases.

    Product Name : Vanrafia

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 02, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves Novartis' Pluvicto for PSMA+ mCRPC Before Chemotherapy

    Details:

    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prostate-specific membrane antigen, which is approved for the treatment of PSMA-positive metastatic castration-resistant prostate cancer.


    Lead Product(s): 177Lu-vipivotide Tetraxetan,68Ga-PSMA-11

    Therapeutic Area: Oncology Brand Name: Pluvicto

    Study Phase: Approved FDFProduct Type: Radiolabelled Compounds

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 28, 2025

    blank

    05

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 177Lu-vipivotide Tetraxetan,68Ga-PSMA-11

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Approves Novartis' Pluvicto for PSMA+ mCRPC Before Chemotherapy

    Details : Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a prostate-specific membrane antigen, which is approved for the treatment of PSMA-positive metastatic castration-resistant prostate cancer.

    Product Name : Pluvicto

    Product Type : Radiolabelled Compounds

    Upfront Cash : Inapplicable

    March 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis’ Fabhalta® FDA Approved for C3 Glomerulopathy (C3G) Treatment

    Details:

    Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is now approved by FDA for the treatment of patients withC3 glomerulopathy.


    Lead Product(s): Iptacopan HCl

    Therapeutic Area: Nephrology Brand Name: Fabhalta

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 20, 2025

    blank

    06

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iptacopan HCl

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis’ Fabhalta® FDA Approved for C3 Glomerulopathy (C3G) Treatment

    Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is now approved by FDA for the treatment of patients withC3 glomerulopathy.

    Product Name : Fabhalta

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Phase III Data Shows Efficacy of Onasemnogene Abeparvovec in SMA

    Details:

    Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.


    Lead Product(s): Onasemnogene Abeparvovec

    Therapeutic Area: Genetic Disease Brand Name: Zolgensma

    Study Phase: Phase IIIProduct Type: Cell and Gene therapy

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 19, 2025

    blank

    07

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Onasemnogene Abeparvovec

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis Phase III Data Shows Efficacy of Onasemnogene Abeparvovec in SMA

    Details : Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.

    Product Name : Zolgensma

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    March 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis oral Fabhalta® (iptacopan) Receives Positive CHMP Opinion

    Details:

    Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.


    Lead Product(s): Iptacopan HCl

    Therapeutic Area: Nephrology Brand Name: Fabhalta

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 28, 2025

    blank

    08

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iptacopan HCl

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis oral Fabhalta® (iptacopan) Receives Positive CHMP Opinion

    Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.

    Product Name : Fabhalta

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront

    Details:

    Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.


    Lead Product(s): Abelacimab

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: $3,075.0 million Upfront Cash: $925.0 million

    Deal Type: Acquisition February 11, 2025

    blank

    09

    Anthos Therapeutics

    U.S.A
    arrow
    Arvo
    Not Confirmed

    Anthos Therapeutics

    U.S.A
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Abelacimab

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : $3,075.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront

    Details : Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.

    Product Name : MAA868

    Product Type : Antibody

    Upfront Cash : $925.0 million

    February 11, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Phase III Study of Onasemnogene Abeparvovec Meets Primary Endpoint in SMA

    Details:

    Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.


    Lead Product(s): Onasemnogene Abeparvovec

    Therapeutic Area: Genetic Disease Brand Name: Zolgensma

    Study Phase: Phase IIIProduct Type: Cell and Gene therapy

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 30, 2024

    blank

    10

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Onasemnogene Abeparvovec

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis Phase III Study of Onasemnogene Abeparvovec Meets Primary Endpoint in SMA

    Details : Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.

    Product Name : Zolgensma

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    December 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : TAVIST ALLERGY/SINUS...

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : TAVIST ALLERGY/SINUS...

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

    Novartis Pharmaceuticals Corporation

    Dosage Form : TABLET;ORAL

    Brand Name : TAVIST ALLERGY/SINUS/HEAD...

    Dosage Strength : 500MG;EQ 0.25MG BASE;3...

    Packaging :

    Approval Date : 2001-03-01

    Application Number : 21082

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : MIOCHOL

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : MIOCHOL

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ACETYLCHOLINE CHLORIDE

    Novartis Pharmaceuticals Corporation

    Dosage Form : FOR SOLUTION;OPHTHALMIC

    Brand Name : MIOCHOL

    Dosage Strength : 20MG/VIAL **Federal Re...

    Packaging :

    Approval Date : 1982-01-01

    Application Number : 16211

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : ACYLANID

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : ACYLANID

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ACETYLDIGITOXIN

    Novartis Pharmaceuticals Corporation

    Dosage Form : TABLET;ORAL

    Brand Name : ACYLANID

    Dosage Strength : 0.1MG

    Packaging :

    Approval Date : 1982-01-01

    Application Number : 9436

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Myfortic

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : Myfortic

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum mycophenolicum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Film-Coated Tablets

    Brand Name : Myfortic

    Dosage Strength : 360mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Myfortic

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : Myfortic

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum mycophenolicum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Film-Coated Tablets

    Brand Name : Myfortic

    Dosage Strength : 180mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Zometa

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : Zometa

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum zoledronicum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Inf Conc

    Brand Name : Zometa

    Dosage Strength : 4mg/5ml

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : TEKAMLO

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : TEKAMLO

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

    Novartis Pharmaceuticals Corporation

    Dosage Form : TABLET;ORAL

    Brand Name : TEKAMLO

    Dosage Strength : EQ 150MG BASE;EQ 5MG B...

    Packaging :

    Approval Date : 2010-08-26

    Application Number : 22545

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : TEKAMLO

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : TEKAMLO

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

    Novartis Pharmaceuticals Corporation

    Dosage Form : TABLET;ORAL

    Brand Name : TEKAMLO

    Dosage Strength : EQ 300MG BASE;EQ 5MG B...

    Packaging :

    Approval Date : 2010-08-26

    Application Number : 22545

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : TEKAMLO

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : TEKAMLO

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

    Novartis Pharmaceuticals Corporation

    Dosage Form : TABLET;ORAL

    Brand Name : TEKAMLO

    Dosage Strength : EQ 150MG BASE;EQ 10MG ...

    Packaging :

    Approval Date : 2010-08-26

    Application Number : 22545

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : TEKAMLO

    Switzerland
    Arvo
    Not Confirmed
    arrow

    Brand Name : TEKAMLO

    Switzerland
    arrow
    Arvo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

    Novartis Pharmaceuticals Corporation

    Dosage Form : TABLET;ORAL

    Brand Name : TEKAMLO

    Dosage Strength : EQ 300MG BASE;EQ 10MG ...

    Packaging :

    Approval Date : 2010-08-26

    Application Number : 22545

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Novartis Pharmaceuticals Corporation and get a quotation

    Novartis Pharmaceuticals Corporation is a supplier offers 71 products (APIs, Excipients or Intermediates).

    Find a price of Pentetreotide bulk with DMF, JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Valsartan bulk with DMF, CEP offered by Novartis Pharmaceuticals Corporation

    Find a price of Amlodipine Besylate bulk with CEP offered by Novartis Pharmaceuticals Corporation

    Find a price of Baclofen bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Cefepime Hydrochloride bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Ceftriaxone bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Cyclosporine bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Fluvastatin bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Glycolide - lactide copolymer bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Letrozole bulk with CEP offered by Novartis Pharmaceuticals Corporation

    Find a price of NAFTIFINE HCL bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Penicillin G Benzathine bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Terbinafine bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Topotecan Hydrochloride bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Benzonatate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Bisoctrizole bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Chlorthalidone bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Clofazimine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Clomipramine Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Edotreotide bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Eudragit Rs bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Methylphenidate Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Naphazoline Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Pyrilamine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Pyrilamine Maleate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Rifampicin bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Thurfyl Nicotinate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of TESSALON DRUG SUBSTANCE bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of CGP 17,582B bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of TINUVIN 326 bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Alpelisib bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Asciminib bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Atorvastatin bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Dabrafenib Mesylate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Deferasirox bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Diclofenac Diethylamine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Everolimus bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Fingolimod Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Fluvastatin Sodium bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Hydrochlorothiazide bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Indacaterol Maleate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Iptacopan Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Ketotifen Fumarate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Lithium Carbonate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Mycophenolate Mofetil bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Mycophenolate Sodium bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Nilotinib bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Osilodrostat Phosphate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Oxcarbazepine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Pimecrolimus bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Ribociclib bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Rivastigmine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Rivastigmine Tartrate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Sacubitril-Valsartan bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Tacrolimus bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Terbinafine Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Trametinib bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Valsartan bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Vildagliptin bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Ashmini hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search